Showing results (151-160 of 156) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 1995
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitorsK Uberla, C Stahl-Hennig, D Böttiger, et al.Proceedings of the National Academy of Sciences of the United States of America|August 1, 1993
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitorsJ Balzarini, A Karlsson, A M Vandamme, et al.Aging & Mental Health|January 30, 2003
The COPE index--a first stage assessment of negative impact, positive value and quality of support of caregiving in informal carers of older peopleK J McKee, I Philp, G Lamura, et al.Virology|January 1, 1993
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptaseJ Balzarini, A Karlsson, M J Pérez-Pérez, et al.Journal of Medicinal Chemistry|October 9, 1999
Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analoguesM Högberg, C Sahlberg, P Engelhardt, et al.Journal of Medicinal Chemistry|October 11, 1996
Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogsA S Cantrell, P Engelhardt, M Högberg, et al.Pageof 16